- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01842035
Heart Rate Response to Regadenoson and Sudden Cardiac Death
Study Overview
Status
Intervention / Treatment
Detailed Description
In patients with heart failure and in those with a history of sudden cardiac death, an Implantable Cardiac Defibrillator (ICD) reduces death rates. However, not all patients with an ICD receive appropriate therapy from it. Inappropriate ICD shocks are common and are associated with worse quality of life and increased death rate. We hope to establish a better predictor of risk of sudden cardiac death and of response to ICD. We are conducting a prospective observational study of 150 patients (18-80 years) with an indication for ICD implantation for primary prevention of sudden cardiac death. Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush.
The main objectives of this proposal are to investigate whether:
- A blunted heart rate response to regadenoson is an independent predictor of sudden cardiac death.
- A blunted heart rate response to regadenoson can be used as a predictor of response to ICD on top of traditionally used indicators.
We Hypothesize that:
- Patients with a blunted heart rate response to regadenoson are at higher risk of sudden cardiac death (death or appropriate cardiac defibrillation). This risk is maintained after controlling for age, gender, left ventricular ejection fraction, heart failure symptoms and medication use.
- Patients with a normal heart rate response to regadenoson have a low rate of events (death or appropriate cardiac defibrillation) despite meeting current indications for having an ICD.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- UAB
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Age 19-80 years
- Female subjects must be (a) at least one year post-menopause or surgically sterile or (b) be non-pregnant and (c) non-lactating.
- Subject must be able and willing to provide written informed consent
Subject must be referred for a clinically indicated ICD and fall into one of the following groups:
- subjects with left ventricular ejection fraction less than 35% due to prior myocardial infarction who are at least 40 days post-myocardial infarction and are in NYHA functional Class II or III.
- subjects with non-ischemic dilated cardiomyopathy who have a left ventricular ejection fraction less than or equal to 35% and who are in NYHA functional Class II or III.
- Subjects with left ventricular dysfunction due to prior myocardial infarction who are at least 40 days post-myocardial infarction, have a left ventricular ejection fraction less than 30%, and are in NYHA functional Class I.
Exclusion Criteria:
- Female subject who is pregnant or lactating
- Subject with active severe asthma or chronic obstructive pulmonary disease which, in the Investigator's opinion, places the subject at risk for severe bronchoconstriction
- Treatment with dipyridamole, theophylline, aminophylline or pentoxifylline within 24 hours of receiving regadenoson
- Treatment with any investigational drug within 30 days or 5 half lives - whichever is longer prior to study entry
- Subject with any prior allergic response to aminophylline or other contraindication to receiving intravenous regadenoson
- Subjects with second or third degree atrioventricular block or dependent on pacemaker
- Subject with uncontrolled severe hypertension (systolic > 200 mmHg or diastolic >120 mmHg) or pretreatment hypotension (systolic BP <90 mmHg)
- Subject with hemodynamically significant aortic stenosis or outflow tract obstruction
- Subject with decompensated heart failure (NYHA functional class IV)
- Subject with acute myocardial infarction, new onset of ischemia, percutaneous coronary intervention, or coronary artery bypass grafting within 30 days of receiving regadenoson
- Subject is on dialysis for end stage renal disease or has an estimated glomerular filtration rate < 15 mL/min
- Subjects with cardiac transplantation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Regadenoson
Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline. -------------------------------------------------------------------------------- |
Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed.
Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush.
Medications (including beta-blockers) will be withheld on the morning of the test.
The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sudden Cardiac Death
Time Frame: Until end of follow-up, median follow-up 40 months
|
Sudden cardiac death will be defined as death within 1 hour of symptom onset, or an unobserved death in which the patient was seen and known to be doing well within 24 hours of death.
Survivors of aborted sudden cardiac death, resuscitated cardiac arrest, and those receiving appropriate ICD therapy will also be considered to have experienced sudden cardiac death and will be included in the primary end point.
|
Until end of follow-up, median follow-up 40 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause Death
Time Frame: Until end of follow-up, median follow-up 40 months
|
death from any cause
|
Until end of follow-up, median follow-up 40 months
|
First Appropriate ICD Therapy
Time Frame: Until end of follow-up, median follow-up 40 months
|
antitachycardia pacing therapy or shock for tachyarrhythmia determined by evaluation of the clinical information and by device diagnostics to be either ventricular fibrillation or ventricular tachycardia
|
Until end of follow-up, median follow-up 40 months
|
Inappropriate ICD Therapy
Time Frame: Until end of follow-up, median follow-up 40 months
|
unnecessary antitachycardia pacing or shock delivered by the ICD for a rhythm that is not a true ventricular fibrillation or ventricular tachycardia
|
Until end of follow-up, median follow-up 40 months
|
All-cause Death or First Appropriate ICD Therapy
Time Frame: Until end of follow-up, median follow-up 40 months
|
death or antitachycardia pacing therapy or shock for tachyarrhythmia determined by evaluation of the clinical information and by device diagnostics to be either ventricular fibrillation or ventricular tachycardia
|
Until end of follow-up, median follow-up 40 months
|
Sudden Cardiac Death or Appropriate ICD Therapy
Time Frame: Until end of follow-up, median follow-up 40 months
|
Sudden cardiac death or antitachycardia pacing therapy or shock for tachyarrhythmia determined by evaluation of the clinical information and by device diagnostics to be either ventricular fibrillation or ventricular tachycardia
|
Until end of follow-up, median follow-up 40 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Fadi G Hage, MD, University of Alabama at Birmingham
Publications and helpful links
General Publications
- Hage FG, Heo J, Franks B, Belardinelli L, Blackburn B, Wang W, Iskandrian AE. Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. Am Heart J. 2009 Apr;157(4):771-6. doi: 10.1016/j.ahj.2009.01.011. Epub 2009 Mar 6.
- Hage FG, Perry G, Heo J, Iskandrian AE. Blunting of the heart rate response to adenosine and regadenoson in relation to hyperglycemia and the metabolic syndrome. Am J Cardiol. 2010 Mar 15;105(6):839-43. doi: 10.1016/j.amjcard.2009.11.042.
- Hage FG, Dean P, Bhatia V, Iqbal F, Heo J, Iskandrian AE. The prognostic value of the heart rate response to adenosine in relation to diabetes mellitus and chronic kidney disease. Am Heart J. 2011 Aug;162(2):356-62. doi: 10.1016/j.ahj.2011.05.014. Epub 2011 Jul 18.
- Hage FG, Dean P, Iqbal F, Heo J, Iskandrian AE. A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging. J Nucl Cardiol. 2011 Dec;18(6):1086-94. doi: 10.1007/s12350-011-9429-1. Epub 2011 Jul 22.
- Iqbal FM, Al Jaroudi W, Sanam K, Sweeney A, Heo J, Iskandrian AE, Hage FG. Reclassification of cardiovascular risk in patients with normal myocardial perfusion imaging using heart rate response to vasodilator stress. Am J Cardiol. 2013 Jan 15;111(2):190-5. doi: 10.1016/j.amjcard.2012.09.013. Epub 2012 Oct 27.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Death, Sudden
- Heart Arrest
- Death
- Death, Sudden, Cardiac
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Purinergic Agents
- Purinergic P1 Receptor Agonists
- Purinergic Agonists
- Adenosine A2 Receptor Agonists
- Regadenoson
Other Study ID Numbers
- REGA 12D05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sudden Cardiac Death
-
Unity Health TorontoSunnybrook Health Sciences Centre; University of British Columbia; Alberta Health... and other collaboratorsCompleted
-
University Hospital Southampton NHS Foundation...WithdrawnCardiac Arrest | Sudden Death, Cardiac
-
Solae, LLCProvident Clinical ResearchCompletedCardiovascular Disease | Sudden Cardiac Death | Sudden Cardiac Arrest
-
Zoll Medical CorporationTerminatedSudden Cardiac Death | Sudden Cardiac ArrestUnited States
-
Solae, LLCProvident Clinical ResearchCompletedCardiovascular Disease | Sudden Cardiac Death | Sudden Cardiac ArrestUnited States
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceRecruitingHeart Failure | Implantable Cardioverter Defibrillator | Primary Prevention of Sudden Cardiac DeathFrance
-
Zoll Medical CorporationCompletedHeart Failure | Sudden Cardiac Death | Sudden Cardiac Arrest | Heart Failure Low OutputFrance, United States, Germany, Austria
-
University of LuebeckProf. Jürgen Kuschyk, M.D; Giovanni Forleo, M.D.; Mauro Biffi, M.D.RecruitingSudden Cardiac DeathGermany
-
Deutsches Herzzentrum MuenchenCompletedSudden Cardiac DeathGermany
-
Jingfeng WangFudan University; The Affiliated Nanjing Drum Tower Hospital of Nanjing University... and other collaboratorsEnrolling by invitation
Clinical Trials on regadenoson
-
University of NebraskaGE Healthcare; Astellas Pharma US, Inc.CompletedCoronary Artery Disease | Myocardial Perfusion AbnormalitiesUnited States
-
Brigham and Women's HospitalCompletedCoronary Artery DiseaseUnited States
-
University of Colorado, DenverCompletedCoronary Artery Disease | Type 1 Diabetes MellitusUnited States
-
VersitiDana-Farber Cancer Institute; University of Illinois at Chicago; Medical College... and other collaboratorsUnknownSickle Cell Disease | Sickle Cell AnemiaUnited States
-
University of Maryland, BaltimoreAstellas Pharma US, Inc.CompletedCardiac FunctionUnited States
-
University of ChicagoAstellas Pharma IncCompleted
-
Christine Lau, MDNational Heart, Lung, and Blood Institute (NHLBI)UnknownLung TransplantUnited States
-
Gilead SciencesTerminatedCoronary Artery Disease | Heart DiseaseUnited Kingdom
-
Ochsner Health SystemAstellas Pharma Global Development, Inc.CompletedCoronary Artery DiseaseUnited States